Voluntis adapts its Corporate Governance and changes its Management Committee

– FRANCE, Paris –  Voluntis (EPA: VTX) today announced changes to its board of directors and management structure as a new step in the implementation of its strategic roadmap announced earlier in March 2020.

The Board of Directors has approved a reduction in its size and as such, Roberta Herman and Nicolas Cartier have resigned as members of the Board of Directors, each of them taking on new leadership roles: Dr Herman as President and CEO of Joslin Diabetes Center and Mr. Cartier as COO of Merieux NutriSciences. This revised Board structure, with six directors of which two are independent, became effective July 30, 2020.

“On behalf of my fellow directors, the company’s management team, and shareholders, I’d like to thank Roberta and Nicolas for the significant contributions they made during their years of service on the Voluntis Board,” said Board Chairman, Eric Elliott, Voluntis. “While we will miss the benefit of their contribution, moving forward, a reduced size of our Board is consistent with our decision to adopt leaner company governance.”

In parallel, the Company organization has been simplified to sustain competitiveness and promote innovation and talents, whilst assuring continuity in the skills, culture and values.

The Executive Committee and the Global Management Committee are now merged into a single Management Committee, led by the CEO, Pierre Leurent. All commercial activities are now headed by Romain Marmot, appointed Chief Business Officer.

As a result of the organizational changes, the COO role has been removed and Alexandre Capet, former COO in Europe, is leaving the company to pursue other interests.

About Voluntis

Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self- manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. These real-time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in diabetes and oncology. Voluntis has long-standing partnerships with leading life science companies. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.

For more information: https://www.voluntis.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.